Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / VIVO - Meridian Bio sees fiscal Q3 revenue of $63.5M below consensus

VIVO - Meridian Bio sees fiscal Q3 revenue of $63.5M below consensus

Meridian Bioscience Inc.
Meridian Bioscience (VIVO) down 2.4% premarket after providing preliminary revenue results for fiscal Q3 2021. The company expects Q3 revenue to be ~$63.5M, below consensus of $73.12M.The Diagnostics segment performance was impacted negatively by supply chain issues with LeadCare reagents that resulted in backorders towards the end of the quarter.The Life Science segment was impacted negatively by the continued reduction in demand for reagents associated with COVID-19 testing. The company will provide full financial results and any changes to fiscal 2021 guidance in Q3 earnings call, scheduled for Friday, August 6, 2021.

For further details see:

Meridian Bio sees fiscal Q3 revenue of $63.5M, below consensus
Stock Information
Company Name: Meridian Bioscience Inc.
Stock Symbol: VIVO
Market: NASDAQ
Website: meridianbioscience.com
Menu
VIVO VIVO Quote VIVO Short VIVO News VIVO Articles VIVO Message Board
Get VIVO Alerts

News, Short Squeeze, Breakout and More Instantly...